Paraneoplastic Autoantibody Testing at an Academic Medical Center

Supplementary file 1: Data for 487 Mayo serum paraneoplastic panel orders (test code: PAVAL) on 483 unique patients. The retrospective timeframe is December 1, 2008 through November 30, 2018. Supplementary file 2: Data for 280 Mayo CSF paraneoplastic panel (test code: PAC1) orders on 276 unique patients. The retrospective timeframe is January 6, 2009 through November 30, 2018. Supplementary file 3: Data for 142 ARUP Laboratories NMDA receptor antibodies in CSF (test code: 2005164) orders on 135 unique patients. The retrospective timeframe is November 19, 2012 through November 30, 2018. Supplementary file 4: Data for 150 ARUP Laboratories NMDA receptor antibodies in serum (test code: 2004221) orders on 144 unique patients. The retrospective timeframe is July 31, 2012 through November 30, 2018. Supplementary file 5: Data for 56 ARUP Laboratories P/Q-type voltage-gated calcium channel (VGCC) antibodies in serum (test code: 2004890) orders on 45 unique patients. The retrospective timeframe is July 25, 2012 through November 30, 2018. Supplementary file 6: Data for 110 ARUP Laboratories serum voltage-gated potassium channel (VGKC) antibodies (test code: 3002046) orders on 107 unique patients. The retrospective timeframe is July 25, 2012 through November 30, 2018. Supplementary file 7: Data for 215 ARUP paraneoplastic reflexive panel in serum (test code: 2013955) orders on 205 unique patients. The retrospective timeframe is October 8, 2015 through November 30, 2018.